The impact of COVID-19 on the management and outcomes of patients with proximal femoral fractures: a multi-centre study of 580 patients.
30-day mortality
COVID-19
Extracapsular hip fracture
Intracapsular hip fracture
Length of stay
Proximal femoral (hip) fracture
Time to theatre
Journal
Journal of orthopaedic surgery and research
ISSN: 1749-799X
Titre abrégé: J Orthop Surg Res
Pays: England
ID NLM: 101265112
Informations de publication
Date de publication:
24 Feb 2021
24 Feb 2021
Historique:
received:
27
11
2020
accepted:
11
02
2021
entrez:
25
2
2021
pubmed:
26
2
2021
medline:
6
3
2021
Statut:
epublish
Résumé
On the 11th March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Multiple new guidelines were proposed and existing models of social, domestic and hospital care altered. Most healthcare systems were largely unprepared for this, and the pandemic has tested their adaptability. This study aimed to assess the impact of COVID-19 on the demographics, presentation, clinical management and outcomes of patients with proximal femoral (hip) fractures comparing them to a similar cohort of patients admitted a year earlier. This retrospective multi-centre cohort study compared all patients admitted with hip fractures between 1st March and 30th May 2019 (group PC: pre-COVID-19) with hip fracture patients admitted over the same time period during the pandemic in 2020 (group C: COVID-19). The data was obtained from the hospitals' local and National Hip Fracture Databases. Mortality data was checked with the Office for National Statistics (ONS). Primary outcomes were time to theatre, in-patient length of stay and 30-day mortality. A total of 580 patients were included (304 group PC, 276 group C). Patient demographics including Charlson Comorbidity Index and Nottingham Hip Fracture Scores were broadly similar across the two cohorts. There was a significant reduction in the percentage of total hip replacements (11 to 5%, p = 0.006) in group C. There was an increase in conservative management (1 to 5%, p = 0.002) in group C. Time to theatre was significantly delayed in group C (43.7 h) vs group PC (34.6 h) (p ≤ 0.001). The overall length of hospital stay was significantly longer in group PC (16.6 days) vs group C (15 days) (p = 0.025). The 30-day mortality rate in group C was 9.8% compared to 8.2% in group PC (p = 0.746), but for COVID-19 (+) patients, it was significantly higher at 38.2% vs 5.8% in COVID-19 (-) patients (p < 0.001). This is one of the largest multi-centre comparative cohort study in the literature to date examining the impact of the COVID-19 pandemic on the management of hip fracture patients. Whilst mortality rates were similar in both groups, COVID-19-positive patients were almost seven times more likely to die, reflecting the seriousness of the COVID-19 infection and its sequelae in such elderly, vulnerable patients.
Sections du résumé
BACKGROUND
BACKGROUND
On the 11th March 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. Multiple new guidelines were proposed and existing models of social, domestic and hospital care altered. Most healthcare systems were largely unprepared for this, and the pandemic has tested their adaptability. This study aimed to assess the impact of COVID-19 on the demographics, presentation, clinical management and outcomes of patients with proximal femoral (hip) fractures comparing them to a similar cohort of patients admitted a year earlier.
METHODS
METHODS
This retrospective multi-centre cohort study compared all patients admitted with hip fractures between 1st March and 30th May 2019 (group PC: pre-COVID-19) with hip fracture patients admitted over the same time period during the pandemic in 2020 (group C: COVID-19). The data was obtained from the hospitals' local and National Hip Fracture Databases. Mortality data was checked with the Office for National Statistics (ONS). Primary outcomes were time to theatre, in-patient length of stay and 30-day mortality.
RESULTS
RESULTS
A total of 580 patients were included (304 group PC, 276 group C). Patient demographics including Charlson Comorbidity Index and Nottingham Hip Fracture Scores were broadly similar across the two cohorts. There was a significant reduction in the percentage of total hip replacements (11 to 5%, p = 0.006) in group C. There was an increase in conservative management (1 to 5%, p = 0.002) in group C. Time to theatre was significantly delayed in group C (43.7 h) vs group PC (34.6 h) (p ≤ 0.001). The overall length of hospital stay was significantly longer in group PC (16.6 days) vs group C (15 days) (p = 0.025). The 30-day mortality rate in group C was 9.8% compared to 8.2% in group PC (p = 0.746), but for COVID-19 (+) patients, it was significantly higher at 38.2% vs 5.8% in COVID-19 (-) patients (p < 0.001).
CONCLUSION
CONCLUSIONS
This is one of the largest multi-centre comparative cohort study in the literature to date examining the impact of the COVID-19 pandemic on the management of hip fracture patients. Whilst mortality rates were similar in both groups, COVID-19-positive patients were almost seven times more likely to die, reflecting the seriousness of the COVID-19 infection and its sequelae in such elderly, vulnerable patients.
Identifiants
pubmed: 33627153
doi: 10.1186/s13018-021-02301-z
pii: 10.1186/s13018-021-02301-z
pmc: PMC7903025
doi:
Types de publication
Comparative Study
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
155Références
Br Med Bull. 2015 Sep;115(1):165-72
pubmed: 26311503
Int Orthop. 2020 Aug;44(8):1543-1547
pubmed: 32440817
Bone Jt Open. 2020 Sep 4;1(9):530-540
pubmed: 33215151
J Bone Joint Surg Am. 2020 Jul 1;102(13):e69
pubmed: 32618917
Acta Biomed. 2020 May 11;91(2):89-96
pubmed: 32420932
J Perioper Pract. 2020 Jul;30(7-8):210-220
pubmed: 32639216
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
J Orthop Surg Res. 2021 Feb 2;16(1):103
pubmed: 33531037
Injury. 2020 Jul;51(7):1414-1418
pubmed: 32405089
Bone Jt Open. 2020 Jun 2;1(6):182-189
pubmed: 33225287
J Bone Joint Surg Am. 2020 May 6;102(9):750-758
pubmed: 32379114
J Orthop Surg Res. 2020 Jun 8;15(1):211
pubmed: 32513216
J Orthop Surg Res. 2020 Jul 28;15(1):285
pubmed: 32723344
J Orthop Surg Res. 2020 Oct 2;15(1):452
pubmed: 33008440
J Bone Joint Surg Am. 2020 Jun 17;102(12):e58
pubmed: 32345864
J Orthop. 2020 Jun 06;21:291-296
pubmed: 32549692
Sci Rep. 2018 Sep 17;8(1):13933
pubmed: 30224765
J Orthop Surg Res. 2020 May 4;15(1):165
pubmed: 32366317
Bone Jt Open. 2020 Nov 04;1(11):697-705
pubmed: 33263109
Patient Saf Surg. 2020 Jul 20;14:30
pubmed: 32695225
J Orthop Surg Res. 2020 Aug 14;15(1):323
pubmed: 32795347
J Orthop Surg Res. 2020 Oct 15;15(1):474
pubmed: 33059739
J Orthop Surg Res. 2020 Aug 12;15(1):322
pubmed: 32787965
J Orthop Surg Res. 2020 May 18;15(1):178
pubmed: 32423471
J Orthop Surg Res. 2020 Jul 23;15(1):279
pubmed: 32703305
JB JS Open Access. 2020 Nov 23;5(4):
pubmed: 33244510
Br J Anaesth. 2011 Apr;106(4):501-4
pubmed: 21278153
J Bone Joint Surg Am. 2020 Jun 3;102(11):946-950
pubmed: 32282412
BMJ Qual Improv Rep. 2014 Sep 19;3(1):
pubmed: 27493729
Bone Joint J. 2020 Sep;102-B(9):1136-1145
pubmed: 32634023